Resource Summary Report

Generated by RRID on Sep 9, 2026

ZR-75-1

RRID:CVCL_0588
Type: Cell Line

Proper Citation

RRID:CVCL_0588

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0588

Proper Citation: RRID:CVCL_0588

Description: Cell line ZR-75-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: PMID:688225, PMID:1911442, PMID:3335022, PMID:6582512, PMID:7902062, PMID:10862037, PMID:10969801, PMID:11044355, PMID:11343771, PMID:12353263, PMID:12800145, PMID:15677628, PMID:15767549, PMID:16397213, PMID:16541312, PMID:17157791, PMID:17334996, PMID:18516279, PMID:19582160, PMID:19593635, PMID:19727395, PMID:20070913, PMID:21378333, PMID:22460905, PMID:22585861, PMID:23601657, PMID:24094812, PMID:24162158, PMID:24176112, PMID:24389870, PMID:25238572, PMID:25485619, PMID:25699542, PMID:25877200, PMID:25960936, PMID:26589293, PMID:26759240, PMID:27378269, PMID:28196595, PMID:28287265, PMID:28889351, PMID:29273624, PMID:30894373, PMID:31068700, PMID:31978347

Comments: Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: JFCR45 cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ZR-75-1

Synonyms: Zr-75-1, ZR751, ZR75-1, ZR75.1, ZR75_1

Cross References: BTO:BTO_0003136, CLO:CLO_0009727, EFO:EFO_0001262, MCCL:MCC:0000494, CLDB:cl4817, CLDB:cl4818, CLDB:cl4819, CLDB:cl4820, CLDB:cl4821, CLDB:cl4946, AddexBio:C0006011/4901, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-1500, BCRC:60055, BioGRID_ORCS_Cell_line:339, BioSample:SAMN01821608, BioSample:SAMN03471337, BioSample:SAMN05292440, BioSample:SAMN10988134, cancercelllines:CVCL_0588, CancerTools:154547, CCRID:1101HUM-PUMC000090, CCRID:3101HUMTCHu126, Cell_Model_Passport:SIDM00314, ChEMBL-Cells:CHEMBL3307615, ChEMBL-Targets:CHEMBL614393, CLS:300163, Cosmic:687503, Cosmic:755295, Cosmic:871152, Cosmic:877452, Cosmic:894094, Cosmic:904398, Cosmic:934532, Cosmic:944296, Cosmic:979717, Cosmic:991333, Cosmic:997927, Cosmic:1010919, Cosmic:1044205, Cosmic:1046930, Cosmic:1047720, Cosmic:1136344, Cosmic:1152530, Cosmic:1175836, Cosmic:1287904, Cosmic:1289421, Cosmic:1309006, Cosmic:1326279, Cosmic:1523772, Cosmic:1524343, Cosmic:1571792, Cosmic:1603229, Cosmic:1609464, Cosmic:2165028, Cosmic:2301536, Cosmic:2318372, Cosmic:2361354, Cosmic:2668279, Cosmic:2750519, Cosmic:2787556, DepMap:ACH-000097, ECACC:87012601, EGA:EGAS00001000610, GEO:GSM73744, GEO:GSM115120, GEO:GSM155214, GEO:GSM217613, GEO:GSM274660, GEO:GSM344360, GEO:GSM344410, GEO:GSM350508, GEO:GSM378142, GEO:GSM383804, GEO:GSM383805, GEO:GSM383806, GEO:GSM388216, GEO:GSM421897, GEO:GSM481332, GEO:GSM783956, GEO:GSM844725, GEO:GSM845400, GEO:GSM847449, GEO:GSM847509, GEO:GSM887750, GEO:GSM888845, GEO:GSM1008921, GEO:GSM1053721, GEO:GSM1172908, GEO:GSM1173004, GEO:GSM1215256, GEO:GSM1238137, GEO:GSM1374993, GEO:GSM1374994, GEO:GSM1374995, GEO:GSM1401648, GEO:GSM1556182, GEO:GSM1556183, GEO:GSM1556184, GEO:GSM1556185, GEO:GSM1556186, GEO:GSM1664567, GEO:GSM2258740, GEO:GSM2258741, GEO:GSM2258742, GEO:GSM2258743, GEO:GSM2258744, GEO:GSM2258745, GEO:GSM2258746, GEO:GSM2258747, GEO:GSM2258748, GEO:GSM2258749, GEO:GSM2258750, GEO:GSM2258751, GEO:GSM2258752, GEO:GSM2258753, GEO:GSM2258754, GEO:GSM2258755, GEO:GSM2258756, GEO:GSM2258757, GEO:GSM2258956, GEO:GSM2258957, GEO:GSM2258958, IARC_TP53:21111, IBRC:C10099, ICLC:HTL99006, IPD-IMGT/HLA:12334, IZSLER:BS TCL 75, KCB:KCB 2010136YJ, KCLB:21500, LiGeA:CCLE_225, LINCS_HMS:50574, LINCS_LDP:LCL-1321, PharmacoDB:ZR751_1689_2019, PRIDE:PXD001327, PRIDE:PXD005390, Progenetix:CVCL_0588, PubChem_Cell_line:CVCL_0588, RCB:RCB1906, SLKBase:3633, TKG:TKG 0189, Wikidata:Q54996114

ID: CVCL_0588

Record Creation Time: 20220427T221743+0000

Record Last Update: 20260905T182855+0000

Ratings and Alerts

No rating or validation information has been found for ZR-75-1.

Warning: Discontinued: RCB; RCB1906
Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: JFCR45 cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1273 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. Cell reports. Medicine, 7(2), 102577.

Peng Y, et al. (2026) SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors. Molecular cancer therapeutics, 25(2), 322.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. Cell reports methods, 101515.

Ohno H, et al. (2026) Label-free imaging of intracellular structures in living mammalian cells via external apodization phase-contrast microscopy. The FEBS journal, 293(4), 1127.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. Molecular oncology.

Herzog SK, et al. (2026) Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer research, 86(7), 1707.

Gao Y, et al. (2026) Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. British journal of pharmacology, 183(11), 3049.

Wang ZW, et al. (2026) Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer. Journal of experimental & clinical cancer research : CR, 45(1).

Zhang D, et al. (2025) Glutamine binds HSC70 to transduce signals inhibiting IFN-??-mediated immunogenic cell death. Developmental cell, 60(14), 1958.

Arnone AA, et al. (2025) Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-?? breast cancer risk. Cell reports. Medicine, 6(1), 101880.

Bhagwat SV, et al. (2025) Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. Cancer research, 85(4), 777.

Alam R, et al. (2025) Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer discovery, 15(4), 818.

Peng Z, et al. (2025) YEATS4 reads histone crotonylation to promote fatty acid metabolism and cancer cell stemness. Cell reports, 44(10), 116400.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Deng N, et al. (2025) Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein. Breast cancer research : BCR, 27(1), 63.

Abayasiriwardana K, et al. (2025) A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. Molecular cancer therapeutics, 24(7), 976.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(7), 1275.

Komar ZM, et al. (2025) Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. Cancers, 17(13).

Hasan MS, et al. (2025) Sequestration and suppressed synthesis of oncogenic HMGA1 using engineered adenoviruses decreases human pancreatic and breast cancer cell characteristics. PloS one, 20(11), e0335934.

Manouchehri JM, et al. (2025) Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP. Cancer biology & therapy, 26(1), 2483989.